Cargando…

Binding Mode and Potency of N-Indolyloxopyridinyl-4-aminopropanyl-Based Inhibitors Targeting Trypanosoma cruzi CYP51

[Image: see text] Chagas disease is a chronic infection in humans caused by Trypanosoma cruzi and manifested in progressive cardiomyopathy and/or gastrointestinal dysfunction. Limited therapeutic options to prevent and treat Chagas disease put 8 million people infected with T. cruzi worldwide at ris...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vieira, Debora F., Choi, Jun Yong, Calvet, Claudia M., Siqueira-Neto, Jair Lage, Johnston, Jonathan B., Kellar, Danielle, Gut, Jiri, Cameron, Michael D., McKerrow, James H., Roush, William R., Podust, Larissa M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2014
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266343/ https://www.ncbi.nlm.nih.gov/pubmed/25393646 http://dx.doi.org/10.1021/jm501568b

Ejemplares similares

4-Aminopyridyl-Based CYP51 Inhibitors as Anti-Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo Potency
por: Calvet, Claudia M., et al.
Publicado: (2014)

Diverse Inhibitor Chemotypes Targeting Trypanosoma cruzi CYP51
por: Gunatilleke, Shamila S., et al.
Publicado: (2012)

Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole
por: Chen, Chiung-Kuang, et al.
Publicado: (2010)

Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen Hit
por: Chen, Chiung-Kuang, et al.
Publicado: (2009)

4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection
por: Calvet, Claudia Magalhaes, et al.
Publicado: (2017)

Long term follow-up of Trypanosoma cruzi infection and Chagas disease manifestations in mice treated with benznidazole or posaconazole
por: Calvet, Claudia Magalhães, et al.
Publicado: (2020)

Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery
por: Ekins, Sean, et al.
Publicado: (2015)

CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM)
por: Debnath, Anjan, et al.
Publicado: (2017)

Drug Strategies Targeting CYP51 in Neglected Tropical Diseases
por: Choi, Jun Yong, et al.
Publicado: (2014)

In Vitro and In Vivo Studies of the Trypanocidal Properties of WRR-483 against Trypanosoma cruzi
por: Chen, Yen Ting, et al.
Publicado: (2010)

High-Throughput Screening of the ReFRAME Library Identifies Potential Drug Repurposing Candidates for Trypanosoma cruzi
por: Bernatchez, Jean A., et al.
Publicado: (2020)

Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity
por: Franco, Caio H., et al.
Publicado: (2020)

Cysteine Protease Inhibitors Cure an Experimental Trypanosoma cruzi Infection
por: Engel, Juan C., et al.
Publicado: (1998)

The Trypanosoma cruzi Protease Cruzain Mediates Immune Evasion
por: Doyle, Patricia S., et al.
Publicado: (2011)

Identification of Leucinostatins from Ophiocordyceps sp. as Antiparasitic Agents against Trypanosoma cruzi
por: Bernatchez, Jean A., et al.
Publicado: (2022)

Targeting Ergosterol Biosynthesis in Leishmania donovani: Essentiality of Sterol 14alpha-demethylase
por: McCall, Laura-Isobel, et al.
Publicado: (2015)

Combination With Tomatidine Improves the Potency of Posaconazole Against Trypanosoma cruzi
por: Rocha-Hasler, Marianne, et al.
Publicado: (2021)

Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development
por: Moraes, Carolina B., et al.
Publicado: (2014)

Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease
por: Riley, Jennifer, et al.
Publicado: (2015)

Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model
por: Dauchy, Frédéric-Antoine, et al.
Publicado: (2016)

Correction: Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model
Publicado: (2017)

The recombinase Rad51 plays a key role in events of genetic exchange in Trypanosoma cruzi
por: Alves, Ceres Luciana, et al.
Publicado: (2018)

Location, Location, Location: Five Facts about Tissue Tropism and Pathogenesis
por: McCall, Laura-Isobel, et al.
Publicado: (2016)

Implication of Apoptosis for the Pathogenesis of Trypanosoma cruzi Infection
por: Decote-Ricardo, Débora, et al.
Publicado: (2017)

Genome-scale metabolic models highlight stage-specific differences in essential metabolic pathways in Trypanosoma cruzi
por: Shiratsubaki, Isabel S., et al.
Publicado: (2020)

Current understanding of the Trypanosoma cruzi-cardiomyocyte interaction
por: Calvet, Claudia M., et al.
Publicado: (2012)

A systematic review of the diagnostic aspects and use of Trypanosoma rangeli as an immunogen for Trypanosoma cruzi infection
por: Bayão, Taciana de Souza, et al.
Publicado: (2020)

The in vivo and in vitro roles of Trypanosoma cruzi Rad51 in the repair of DNA double strand breaks and oxidative lesions
por: Gomes Passos Silva, Danielle, et al.
Publicado: (2018)

Profiling the Trypanosoma cruzi Phosphoproteome
por: Marchini, Fabricio K., et al.
Publicado: (2011)

Clathrin expression in Trypanosoma cruzi
por: Kalb, Ligia Cristina, et al.
Publicado: (2014)

Endothelial Transmigration by Trypanosoma cruzi
por: Coates, Bria M., et al.
Publicado: (2013)

The N-myristoylome of Trypanosoma cruzi
por: Roberts, Adam J., et al.
Publicado: (2016)

Molecular dissection of Chagas induced cardiomyopathy reveals central disease associated and druggable signaling pathways
por: Wozniak, Jacob M., et al.
Publicado: (2020)

In vitro anti-Trypanosoma cruzi activity enhancement of curcumin by its monoketone tetramethoxy analog diveratralacetone
por: Souza, Julia M., et al.
Publicado: (2021)

An Image-Based Algorithm for Precise and Accurate High Throughput Assessment of Drug Activity against the Human Parasite Trypanosoma cruzi
por: Moon, Seunghyun, et al.
Publicado: (2014)

Oral Transmission of Trypanosoma cruzi, Brazilian Amazon
por: Santana, Rosa Amélia G., et al.
Publicado: (2019)

Specific inhibition of the differentiation of Trypanosoma cruzi
Publicado: (1984)

OBSERVATIONS ON THE RESPIRATION OF TRYPANOSOMA CRUZI IN CULTURE
por: von Brand, Theodor, et al.
Publicado: (1946)

Autochthonous Transmission of Trypanosoma cruzi, Louisiana
por: Dorn, Patricia L., et al.
Publicado: (2007)

Flagellar Motility of Trypanosoma cruzi Epimastigotes
por: Ballesteros-Rodea, G., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_alat2t7gva4472reea03a39kms